Business
AI clinical monitoring agent can deliver up to 82 times the ROI in oncology: report - Fierce Biotech

What the report says
A new analysis from the Tufts Center for the Study of Drug Development (CSDD) found that an AI clinical monitoring agent can deliver 82 times the return on investment (ROI) in oncology trials. | A new analysis from the Tufts Center for the Study of Drug Devel…
Loading debate for this article…
Other publishers covering this story
No additional verified coverage is currently clustered with this report.

Equity Group roadshow seeks to unlock cross-border trade and investmentNile Post
Equity trade mission puts Uganda’s investment potential in spotlightNile Post
Ibanda Traders Report Slow Scholastic Sales as Third Term OpensNile Post